Roche and GlaxoSmithKline have inked a licensing deal for the obesity drug Orlistat while agreeing to drop litigation over a separate licensing deal. Roche provided an unspecified settlement to GSK. GSK gained the exclusive non-prescription rights to Orlistat outside of the U.S. and Japan. And all claims regarding the marketing of Carvedilol were dropped.
- here's the MarketWatch report on the settlement